We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Technique to Insure Stable Supply of Flu Drug

By Biotechdaily staff writers
Posted on 31 Mar 2006
A team of Japanese researchers has developed a new technique for producing the anti-flu drug Tamiflu (ostelamivir) that does not rely on natural ingredients, which may help ensure a more stable supply of the drug in the event of a pandemic.

Researchers at the University of Tokyo's Graduate School of Pharmaceutical Sciences (Japan) have found a way to manufacture Tamiflu without using shikimic acid, produced from a spice called star anise. More...
This brownish star-shaped fruit of the illicium verum tree is often used as a spice in Chinese cuisine. The new technique, called asymmetric catalysis, produces Tamiflu from a petrochemical ingredient called 1,4-cyclohexadiene instead, eliminating weather as a risk factor in Tamiflu production. Tamiflu, produced by Roche (Basel, Switzerland), is considered one of the best defenses against avian flu in humans.

If things go well, I hope we may be able to pave the way towards giving supplies to society in around two years, said Professor Masakatsu Shibasaki, a biochemist and leader of the team that developed the process, adding that he would soon submit a paper on his team's findings to the Journal of the American Chemical Society. Tokyo University has applied for an intellectual property patent in Japan and is now in discussions with Roche on a number of issues regarding further research and licensing.

Asymmetric catalysis is a chemical-reaction process invented by Professor Ryoji Noyori, now president of the Riken Institute (Saitama, Japan), a multi-site Japanese research initiative with an annual budget of U.S.$800 million. He was awarded the 2001 Nobel Prize in chemistry for his development of the process.



Related Links:
U. of Tokyo Grad. School of Pharmaceutical Sciences

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.